Method for treating neurological and neuropathic diseases using rho kinase inhibitor compounds
This invention is directed to methods of preventing or treating neurological or neuropathic diseases or conditions associated with excessive inflammation, neurodegeneration, neuro-remodeling, and axonal/neurite retraction. Particularly, this invention relates to methods treating neurological or neuropathic diseases such as cerebral ischemia, stroke, neuropathic pain, spinal cord injury, Alzheimer's disease, and multiple sclerosis, using novel rho kinase inhibitor compounds. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a novel rho kinase inhibitor compound to treat the disease.
1. A method of treating nociceptive pain, the method comprises the steps of first identifying a subject suffering from nociceptive pain, then administering to the subject an effective amount of a compound of Formula II to treat nociceptive pain;
wherein:
Q is (CR 4 R 5 ) n3 ;
n 1 is 1;
n 2 is 1;
n 3 is 0, 1, 2, or 3;
R 2 is R 2 -2, optionally substituted:
Ar is indazole;
X is from 1 to 3 substituents on Ar, each independently in the form Y—Z, in which Z is attached to Ar;
Y is one or more substituents on Z, and each is independently OR 8 , NR 8 R 9 , NO 2 , SR 8 , SOR 8 , SO 2 R 8 , SO 2 NR 8 R 9 , NR 8 SO 2 R 9 , OCF 3 , CONR 8 R 9 , NR 8 C(═O)R 9 , NR 8 C(═O)OR 9 , OC(═O)NR 8 R 9 , or NR 8 C(═O)NR 9 R 10 ,
Z is alkyl, alkenyl, alkynyl, aryl, or cycloalkyl;
R 3 -R 5 are independently H, alkyl, or cycloalkyl, optionally substituted;
R 8 -R 10 are independently H, alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, (heterocycle)alkyl, (heterocycle)alkenyl, (heterocycle)alkynyl, or heterocycle.
2. The method according to claim 1 , wherein said compound is Compound 2.058, which is (R)-2-(6-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)-1H-indol-1-yl)acetamide; Compound 2.059, which is (R)-2-(5-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)-1H-indol-1-yl)acetamide; Compound 2.060, which is (R)-2-(6-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)-1H-indol-1-yl)ethanol; Compound 2.066, which is (R)-2-(5-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)-1H-indol-1-yl)ethanol; or Compound 2.072, which is (R)-2-(3-((3-(isoquinolin-5-ylamino)pyrrolidin-1-yl)methyl)-1H-indol-1-yl)ethanol.
3. The method according to claim 1 , wherein n 3 is 1 or 2.
4. The method according to claim 2 , wherein said compound is Compound 2.066.
5. The method according to claim 1 , wherein Y is OR 8 .
6. The method according to claim 1 , wherein Y is CONR 8 R 9 .
7. The method according to claim 2 , wherein said compound is Compound 2.059.